atenolol has been researched along with Cardiac Failure in 60 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 9.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 9.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| "We compared the effects of 6 months administration of atenolol or nebivolol on resting and exercise hemodynamic parameters and maximal exercise capacity, in 26 patients with hypertension and left ventricular (LV) diastolic dysfunction (ejection fraction >50%, end-diastolic diameter <60 mm and increased pulmonary wedge pressure at rest and/or at peak exercise)." | 9.10 | Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. ( Dei Cas, L; Metra, M; Nodari, S, 2003) |
| "One hundred and nineteen patients with class II or III heart failure, left ventricular ejection fraction < or = 25% and treatment with 40 mg enalapril daily were given an initial challenge dose of atenolol 12." | 9.09 | Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. ( Berger, R; Frey, B; Pacher, R; Stanek, B; Strametz-Juranek, J; Sturm, B, 2000) |
| "Beta-blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin." | 7.73 | Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. ( Berlowitz, DR; Cunningham, F; Gomez-Caminero, A; Miller, DR; Oliveria, SA; Rothendler, JA, 2006) |
| "The paper demonstrates that the hydrophilic beta-adrenoblocker (BAB) atenolol is effective in patients with III-IV functional class chronic heart failure (CHF), associated with postinfarction cardiosclerosis (PIC) and dilatational cardiomyopathy (DC)." | 7.73 | [Influence of therapy with atenolol on lethality of patients with chronic heart failure]. ( Aleksinskaia, TV; Syrkin, AL; Syrkina, EA; Vyshinskaia, ID, 2005) |
| "The efficacy of MCI-154, a new pyridazinone cardiotonic agent, in improving heart failure was assessed in dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital." | 7.67 | Improvement of pentobarbital-induced heart failure by MCI-154, a novel and potent cardiotonic agent, in the dog heart-lung preparation. ( Goto, T; Hashimoto, H; Hosono, M; Nunoki, K; Sato, Y; Satoh, K; Taira, N, 1988) |
| "Atenolol is a long-acting cardioselective beta-blocking agent and is devoid of additional vasodilatory properties." | 6.68 | Effects of atenolol as add-on therapy to fosinopril in heart failure. ( Berger, R; Dukat, A; Frey, B; Hülsmann, M; Koller-Strametz, J; Kos, T; Pacher, R; Stanek, B, 1997) |
| "Beta-blockers have solid documentation in preventing cardiovascular complications in the treatment of hypertension; atenolol, metoprolol, oxprenolol and propranolol demonstrate proven cardiovascular prevention in hypertension mega-trials." | 5.22 | Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified. ( Esler, M; Grassi, G; Kjeldsen, SE; Kreutz, R; Mancia, G; Pathak, A, 2022) |
| "All-cause mortality was examined in relation to in-treatment digoxin use in 937 hypertensive patients with ECG left ventricular hypertrophy in atrial fibrillation at baseline (n = 134) or who developed atrial fibrillation during follow-up (n = 803), randomly assigned to losartan or atenolol-based treatment, in post-hoc analysis of a substudy of the Losartan Intervention For Endpoint Reduction in hypertension (LIFE) trial." | 5.20 | Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation. ( Boman, K; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2015) |
| "A total of 9,027 patients with hypertension and ECG-LVH and without a history of HF were randomized to losartan- or atenolol-based treatment in the Losartan Intervention For Endpoint reduction in hypertension study." | 5.16 | Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Larstorp, AC; Okin, PM; Olsen, MH; Wachtell, K, 2012) |
| "The relation of QRS over time to incident heart failure was examined in 8945 hypertensive patients without history of heart failure who were randomly assigned to losartan-based or atenolol-based treatment." | 5.14 | Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study. ( Dahlöf, B; Devereux, RB; Edelman, JM; Kjeldsen, SE; Okin, PM, 2009) |
| "The relation of ECG strain and albuminuria to new-onset HF was examined in 7,786 hypertensive patients with no history of HF, who were randomly assigned to treatment with losartan or atenolol." | 5.13 | Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Devereux, RB; Ibsen, H; Julius, S; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Oikarinen, L; Okin, PM; Olsen, MH; Toivonen, L; Viitasalo, M; Wachtell, K, 2008) |
| "To determine whether beta-blocker dose influences cardiac collagen turnover and the effects of spironolactone on cardiac collagen turnover in patients with heart failure." | 5.12 | Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure. ( Camp, JR; Cavallari, LH; Groo, VL; Momary, KM; Stamos, TD; Viana, MA, 2007) |
| "Losartan Intervention For Endpoint reduction in hypertension study." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. ( Dahlöf, B; Devereux, RB; Edelman, JM; Harris, KE; Jern, S; Julius, S; Kjeldsen, SE; Okin, PM, 2007) |
| "We sought to study the risk factors for heart failure (HF) and the relation between antihypertensive treatment with losartan and the first hospitalization for HF in patients with diabetes mellitus in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) and Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) studies." | 5.11 | Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. ( Brenner, BM; Carr, AA; Dahlöf, B; Devereux, RB; Edelman, JM; Ibsen, H; Kowey, PR; Lindholm, LH; Lyle, PA; Shahinfar, S; Snapinn, SM; Zhang, Z, 2005) |
| "We compared the effects of 6 months administration of atenolol or nebivolol on resting and exercise hemodynamic parameters and maximal exercise capacity, in 26 patients with hypertension and left ventricular (LV) diastolic dysfunction (ejection fraction >50%, end-diastolic diameter <60 mm and increased pulmonary wedge pressure at rest and/or at peak exercise)." | 5.10 | Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. ( Dei Cas, L; Metra, M; Nodari, S, 2003) |
| "To evaluate efficiency of using ACE inhibitor (capoten) and beta-blocker (atenolol) in diverse mitral and aortic valve defects (MVD and AVD, respectively) of rheumatic etiology complicated by chronic cardiac failure (CCF) of the first and second stages." | 5.09 | [Treatment of chronic heart failure in patients with mitral and aortic valve defects of rheumatic origin]. ( Bagirova, GG; Batalina, MV, 2000) |
| "One hundred and nineteen patients with class II or III heart failure, left ventricular ejection fraction < or = 25% and treatment with 40 mg enalapril daily were given an initial challenge dose of atenolol 12." | 5.09 | Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. ( Berger, R; Frey, B; Pacher, R; Stanek, B; Strametz-Juranek, J; Sturm, B, 2000) |
| "Plasma hormones were measured at baseline and months 3, 6, 12 and 24 in 91 patients with heart failure (left ventricular ejection fraction [LVEF] <25%) receiving 40 mg enalapril/day and double-blind atenolol (50 to 100 mg/day) or placebo." | 5.09 | Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. ( Berger, R; Bergler-Klein, J; Bojic, A; Frey, B; Hartter, E; Hülsmann, M; Moser, P; Pacher, R; Stanek, B; Strametz-Juranek, J; Sturm, B, 2001) |
| "In older persons with isolated systolic hypertension, stepped-care treatment based on low-dose chlorthalidone exerted a strong protective effect in preventing heart failure." | 5.08 | Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. ( Applegate, WB; Berge, KG; Berkson, DM; Black, HR; Blaufox, MD; Cohen, JD; Curb, JD; Cutler, J; Davis, BR; Grimm, RH; Kostis, JB; Lacy, CR; McDonald, R; Perry, HM; Schron, E; Smith, WM; Wassertheil-Smoller, S, 1997) |
| " β blockers, alone or in combination with digoxin, or non-dihydropyridine calcium-channel blockers (not in heart failure) effectively lower the heart rate." | 4.93 | Rate control in atrial fibrillation. ( Crijns, HJ; Olshansky, B; Rienstra, M; Van Gelder, IC, 2016) |
| " We also now have another bradycardic agent, ivabradine, which may prove very useful in heart failure patients who cannot tolerate a betablocker." | 4.84 | [What are the alternatives to betablockers in 2009?]. ( van de Borne, P, 2008) |
| " The following issues are reported in detail: (1) significance of statins, inhibition of platelet aggregation and vitamins in primary and secondary prevention of cardiovascular disease, (2) comparison of the angiotensin receptor blocker losartan and the beta-blocker atenolol in hypertension (LIFE study), (3) magnetic resonance angiography for the detection of coronary stenoses, (4) advantages and disadvantages of operative and interventional coronary revascularization considering elderly patients and sirolimus-eluting stents, and (5) efficacy of glycoprotein IIb/IIIa inhibition and low molecular weight heparin in acute myocardial infarction." | 4.82 | [From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I]. ( Böhm, M; Fries, R, 2003) |
| " Three weeks after inducing myocardial infarction (MI), rats were treated daily with or without 20 and 75 mg/kg atenolol, a selective β(1) -AR antagonist, or propranolol, a non-selective β-AR antagonist, for 5 weeks." | 3.77 | β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure. ( Dhalla, NS; Elimban, V; Machackova, J; Sanganalmath, SK, 2011) |
| "The paper demonstrates that the hydrophilic beta-adrenoblocker (BAB) atenolol is effective in patients with III-IV functional class chronic heart failure (CHF), associated with postinfarction cardiosclerosis (PIC) and dilatational cardiomyopathy (DC)." | 3.73 | [Influence of therapy with atenolol on lethality of patients with chronic heart failure]. ( Aleksinskaia, TV; Syrkin, AL; Syrkina, EA; Vyshinskaia, ID, 2005) |
| "The authors of the article studied potential of various drug combinations (atenolol + enalapril + indapamide, and celanid + enalapril + indapamide) in complex treatment of patients with heart failure (HF) and supraventricular arrhythmias." | 3.73 | [Cardiac glycosides in complex treatment of patients with heart failure and supraventricular arrhythmias]. ( Kremnev, IuA; Podshibiakin, SE; Zamotaev, IuN, 2005) |
| "Beta-blockers have many different physiologic effects that could potentially influence the risk of hemorrhagic events in chronic heart failure patients (CHF) on warfarin." | 3.73 | Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. ( Berlowitz, DR; Cunningham, F; Gomez-Caminero, A; Miller, DR; Oliveria, SA; Rothendler, JA, 2006) |
| "A 24-hour Holter ECG recording was obtained before and 1 and 3 months after titrated addition of atenolol therapy in 10 consecutive patients with advanced congestive heart failure." | 3.72 | Restoration of heart rate turbulence by titrated beta-blocker therapy in patients with advanced congestive heart failure: positive correlation with enhanced vagal modulation of heart rate. ( Chan, HL; Du, CC; Hwang, JJ; Lai, LP; Lin, JL; Lin, LY; Tseng, YZ, 2004) |
| "Sequential 24-hour Holter ECG recordings were obtained at baseline, and 1 and 3 months after addition of atenolol therapy for advanced congestive heart failure in 10 patients." | 3.71 | Reversal of deteriorated fractal behavior of heart rate variability by beta-blocker therapy in patients with advanced congestive heart failure. ( Du, CC; Huang, SK; Lai, LP; Lin, JL; Lin, LY; Tseng, YZ, 2001) |
| "To respond to clinical concern about worsening autonomic nervous perturbation in beta-blocker therapy of advanced congestive heart failure, 15 consecutive patients were longitudinally studied to elucidate the evolution of cardiac function versus 24-hour heart rate variability (HRV) before and after 1, 3, and 6 to 9 months of atenolol-combined therapy." | 3.70 | Long-term beta-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study. ( Chan, HL; Du, CC; Lai, CW; Lien, WP; Lin, IN; Lin, JL; Lin, KT; Tseng, YZ; Wu, CP, 1999) |
| "The efficacy of MCI-154, a new pyridazinone cardiotonic agent, in improving heart failure was assessed in dog heart-lung preparations in which cardiac function had been severely depressed by pentobarbital." | 3.67 | Improvement of pentobarbital-induced heart failure by MCI-154, a novel and potent cardiotonic agent, in the dog heart-lung preparation. ( Goto, T; Hashimoto, H; Hosono, M; Nunoki, K; Sato, Y; Satoh, K; Taira, N, 1988) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "Atenolol is a long-acting cardioselective beta-blocking agent and is devoid of additional vasodilatory properties." | 2.68 | Effects of atenolol as add-on therapy to fosinopril in heart failure. ( Berger, R; Dukat, A; Frey, B; Hülsmann, M; Koller-Strametz, J; Kos, T; Pacher, R; Stanek, B, 1997) |
| "Heart failure is characterized by the inability of the myocardium to shorten sufficiently or to eject an adequate stroke volume to maintain normal perfusion of both the cardiac and the extracardiac organs." | 2.38 | Beta-blocking agents in heart failure: modern concepts and overview. ( Strauer, BE, 1990) |
| "Pharmacological treatment for heart failure involves different drugs as: angiotensin-converting enzyme inhibitors, B-adrenergic blockers, digitalis glycosides and diuretics." | 1.46 | [Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications] ( Baez, A; Bazán, C; Camino Willhuber, GO; Fretes, R; Guzman Mentesana, G; Lo Presti, S; Paglini-Oliva, PA; Rivarola, HW; Strauss, M, 2017) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| " This dosage schedule for beta-blockade was chosen because catecholamines are persistently elevated by day 14 in this model of CHF." | 1.29 | Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure. ( Hebbar, L; Johnson, WS; Jones, BU; Mukherjee, R; Spinale, FG; Wang, Y; Wang, Z, 1996) |
| " All patients were treated with atenolol at dosage of 50 mg/die." | 1.28 | [Neurohumoral changes in patients with heart failure treated chronically with beta-blockers]. ( Mattioli, AV; Mattioli, G, 1991) |
| "In patients with congestive heart failure (CHF) sympathetic reflexes are attenuated because of down regulation of beta receptors." | 1.28 | [Hemodynamic effects of the nitroprusside test in chronic congestive heart failure treated with long-term beta blocking therapy]. ( Bettelli, G; Cappello, C; Mattioli, AV; Mattioli, G, 1990) |
| "In atenolol-treated subjects the sympathetic response is strongly attenuated." | 1.28 | [Hemodynamic effects of the cold pressor test in patients with heart failure treated with beta blockers for a long time]. ( Bettelli, G; Cappello, C; Mattioli, AV; Mattioli, G, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (8.33) | 18.7374 |
| 1990's | 10 (16.67) | 18.2507 |
| 2000's | 32 (53.33) | 29.6817 |
| 2010's | 11 (18.33) | 24.3611 |
| 2020's | 2 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Voets, M | 1 |
| Antes, I | 1 |
| Scherer, C | 1 |
| Müller-Vieira, U | 1 |
| Biemel, K | 1 |
| Marchais-Oberwinkler, S | 1 |
| Hartmann, RW | 1 |
| Esler, M | 1 |
| Kjeldsen, SE | 7 |
| Pathak, A | 1 |
| Grassi, G | 1 |
| Kreutz, R | 1 |
| Mancia, G | 1 |
| Zhou, H | 1 |
| Sim, JJ | 1 |
| Shi, J | 1 |
| Shaw, SF | 1 |
| Lee, MS | 2 |
| Neyer, JR | 1 |
| Kovesdy, CP | 1 |
| Kalantar-Zadeh, K | 1 |
| Jacobsen, SJ | 1 |
| Duan, L | 1 |
| Ng, A | 1 |
| Chen, W | 1 |
| Spencer, HT | 1 |
| Nguyen, J | 1 |
| Shen, AY | 1 |
| Camino Willhuber, GO | 1 |
| Guzman Mentesana, G | 1 |
| Baez, A | 1 |
| Lo Presti, S | 1 |
| Bazán, C | 1 |
| Strauss, M | 1 |
| Fretes, R | 1 |
| Paglini-Oliva, PA | 1 |
| Rivarola, HW | 1 |
| Bang, CN | 1 |
| Gerdts, E | 1 |
| Aurigemma, GP | 1 |
| Boman, K | 2 |
| de Simone, G | 1 |
| Dahlöf, B | 8 |
| Køber, L | 1 |
| Wachtell, K | 4 |
| Devereux, RB | 8 |
| Okin, PM | 6 |
| Hille, DA | 1 |
| Van Gelder, IC | 1 |
| Rienstra, M | 1 |
| Crijns, HJ | 1 |
| Olshansky, B | 1 |
| Zacà, V | 1 |
| Rastogi, S | 1 |
| Mishra, S | 1 |
| Wang, M | 1 |
| Sharov, VG | 1 |
| Gupta, RC | 1 |
| Goldstein, S | 1 |
| Sabbah, HN | 1 |
| van de Borne, P | 1 |
| Sal'nikov, EV | 1 |
| Edelman, JM | 4 |
| Machackova, J | 2 |
| Sanganalmath, SK | 2 |
| Barta, J | 1 |
| Dhalla, KS | 1 |
| Dhalla, NS | 2 |
| Elimban, V | 1 |
| Oikarinen, L | 2 |
| Viitasalo, M | 2 |
| Toivonen, L | 2 |
| Nieminen, MS | 2 |
| Li, P | 1 |
| Robertson, TA | 1 |
| Zhang, Q | 1 |
| Fletcher, LM | 1 |
| Crawford, DH | 1 |
| Weiss, M | 1 |
| Roberts, MS | 1 |
| Larstorp, AC | 1 |
| Olsen, MH | 2 |
| Ibsen, H | 3 |
| Fries, R | 1 |
| Böhm, M | 1 |
| Ajayi, AA | 2 |
| Sofowora, GG | 2 |
| Adigun, AQ | 2 |
| Asiyanbola, B | 2 |
| Yilmaz, M | 1 |
| Gurlertop, Y | 1 |
| Acikel, M | 1 |
| Erol, K | 1 |
| Bozkurt, E | 1 |
| Sevimli, S | 1 |
| Senocak, H | 1 |
| Nodari, S | 1 |
| Metra, M | 1 |
| Dei Cas, L | 1 |
| Lin, LY | 3 |
| Hwang, JJ | 2 |
| Lai, LP | 2 |
| Chan, HL | 2 |
| Du, CC | 3 |
| Tseng, YZ | 3 |
| Lin, JL | 4 |
| Saxon, LA | 1 |
| Syrkina, EA | 1 |
| Vyshinskaia, ID | 1 |
| Aleksinskaia, TV | 1 |
| Syrkin, AL | 1 |
| Zamotaev, IuN | 1 |
| Kremnev, IuA | 1 |
| Podshibiakin, SE | 1 |
| Carr, AA | 1 |
| Kowey, PR | 1 |
| Brenner, BM | 1 |
| Lindholm, LH | 2 |
| Lyle, PA | 1 |
| Snapinn, SM | 1 |
| Zhang, Z | 1 |
| Shahinfar, S | 1 |
| Weber, MA | 1 |
| Baumgart, P | 1 |
| Davis, BR | 2 |
| Piller, LB | 1 |
| Cutler, JA | 1 |
| Furberg, C | 1 |
| Dunn, K | 1 |
| Franklin, S | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Papademetriou, V | 1 |
| Proschan, M | 1 |
| Ellsworth, A | 1 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Lin, JW | 1 |
| Berlowitz, DR | 1 |
| Miller, DR | 1 |
| Oliveria, SA | 1 |
| Cunningham, F | 1 |
| Gomez-Caminero, A | 1 |
| Rothendler, JA | 1 |
| Cavallari, LH | 1 |
| Momary, KM | 1 |
| Groo, VL | 1 |
| Viana, MA | 1 |
| Camp, JR | 1 |
| Stamos, TD | 1 |
| Go, AS | 1 |
| Yang, J | 1 |
| Gurwitz, JH | 1 |
| Hsu, J | 1 |
| Lane, K | 1 |
| Platt, R | 1 |
| Harris, KE | 1 |
| Jern, S | 1 |
| Julius, S | 2 |
| Borch-Johnsen, K | 1 |
| Aronson, JK | 1 |
| Sleight, P | 1 |
| Robson, RH | 1 |
| Vishwanath, MC | 1 |
| Spinale, FG | 1 |
| Johnson, WS | 1 |
| Wang, Y | 1 |
| Wang, Z | 1 |
| Mukherjee, R | 1 |
| Hebbar, L | 1 |
| Jones, BU | 1 |
| Pacher, R | 4 |
| Hülsmann, M | 3 |
| Berger, R | 4 |
| Koller-Strametz, J | 1 |
| Kos, T | 1 |
| Frey, B | 4 |
| Dukat, A | 1 |
| Stanek, B | 4 |
| Kostis, JB | 1 |
| Cutler, J | 1 |
| Grimm, RH | 1 |
| Berge, KG | 1 |
| Cohen, JD | 1 |
| Lacy, CR | 1 |
| Perry, HM | 1 |
| Blaufox, MD | 1 |
| Wassertheil-Smoller, S | 1 |
| Black, HR | 1 |
| Schron, E | 1 |
| Berkson, DM | 1 |
| Curb, JD | 1 |
| Smith, WM | 1 |
| McDonald, R | 1 |
| Applegate, WB | 1 |
| Levine, TB | 1 |
| Levine, AB | 1 |
| Keteyian, SJ | 1 |
| Narins, B | 1 |
| Lin, IN | 1 |
| Lai, CW | 1 |
| Lin, KT | 1 |
| Wu, CP | 1 |
| Lien, WP | 1 |
| Du, XJ | 1 |
| Cox, HS | 1 |
| Dart, AM | 1 |
| Esler, MD | 1 |
| Bagirova, GG | 1 |
| Batalina, MV | 1 |
| Strecker, K | 1 |
| Sturm, B | 2 |
| Strametz-Juranek, J | 2 |
| Huang, SK | 1 |
| Bergler-Klein, J | 1 |
| Moser, P | 1 |
| Bojic, A | 1 |
| Hartter, E | 1 |
| Strauer, BE | 1 |
| Uusimaa, P | 1 |
| Tokola, H | 1 |
| Ruskoaho, H | 1 |
| Vuolteenaho, O | 1 |
| Risteli, J | 1 |
| Ylitalo, A | 1 |
| Peuhkurinen, K | 1 |
| Reybrouck, T | 1 |
| Amery, A | 1 |
| Billiet, L | 1 |
| Fagard, R | 1 |
| Mattioli, AV | 3 |
| Mattioli, G | 3 |
| Cappello, C | 2 |
| Bettelli, G | 2 |
| Wolf, R | 1 |
| Ophir, J | 1 |
| Elman, M | 1 |
| Krakowski, A | 1 |
| Satoh, K | 1 |
| Nunoki, K | 1 |
| Goto, T | 1 |
| Hosono, M | 1 |
| Hashimoto, H | 1 |
| Sato, Y | 1 |
| Taira, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Effects of Nebivolol Versus Metoprolol on Blood Flow Responses to Exercise and Angiotensin II in Hypertensive Patients[NCT01502787] | Phase 4 | 46 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Alternative in Beta Blocker Intolerance; the ABBI Trial[NCT00893984] | Phase 4 | 6 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Lack of patient recruitment) | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [NCT00000514] | Phase 3 | 0 participants | Interventional | 1984-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01502787)
Timeframe: 12 weeks after initiation of metoprolol
| Intervention | mmHg (Mean) |
|---|---|
| Metoprolol | 114 |
| Nebivolol | 113 |
(NCT01502787)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Initial Treatment With Metoprolol | 101 |
| Initial Treatment With Nebivolol | 103 |
(NCT01502787)
Timeframe: 12 weeks after each specified medication
| Intervention | ml/min (Mean) |
|---|---|
| First Intervention Metoprolol: 12 Weeks | 96 |
| Second Intervention Nebivolol: 24 Weeks | 105 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
Mild symptoms include weight gain, edema, and headaches (NCT00893984)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Nebivolol | 1 |
(NCT00893984)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Nebivolol | 0 |
6 reviews available for atenolol and Cardiac Failure
| Article | Year |
|---|---|
Diverse pharmacological properties, trial results, comorbidity prescribing and neural pathophysiology suggest European hypertension guideline downgrading of beta-blockers is not justified.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Comorbidity | 2022 |
Rate control in atrial fibrillation.
Topics: Adrenergic beta-Antagonists; Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atenolol; Atrial Fibri | 2016 |
[What are the alternatives to betablockers in 2009?].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzazepines; Cardiomyopathies; Heart Failur | 2008 |
[From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002--part I].
Topics: Abciximab; Adult; Age Factors; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; An | 2003 |
The role of the new beta-blockers in treating cardiovascular disease.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans | 2005 |
Beta-blocking agents in heart failure: modern concepts and overview.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Coronary Disease; Heart Failure; Hemodynamics; Human | 1990 |
20 trials available for atenolol and Cardiac Failure
| Article | Year |
|---|---|
Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Atenolol; Cause of Death; De | 2014 |
Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure | 2015 |
Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study.
Topics: Aged; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography; Female; Heart Fai | 2009 |
Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Double-Blind Method; Electrocardiography | 2011 |
Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Female; Heart Failure; Humans; Hypertens | 2012 |
Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal reflex activity.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2003 |
Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Echocardiography; | 2003 |
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Ateno | 2005 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
Measuring heart rate variability with wavelet thresholds and energy components in healthy subjects and patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Electrocardiography, Ambulatory; Energy Metaboli | 2006 |
Association of beta-blocker dose with serum procollagen concentrations and cardiac response to spironolactone in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Carbazoles; Carvedilol; Diuretics; Dose-Response | 2007 |
Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Drug Therapy, Combination; Electrocardio | 2007 |
Combination of the electrocardiographic strain pattern and albuminuria for the prediction of new-onset heart failure in hypertensive patients: the LIFE study.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blin | 2008 |
Beta-blockade in acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Clinical Trials as Topic; Creatine Kinase; Elect | 1982 |
Effects of atenolol as add-on therapy to fosinopril in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Dose-R | 1997 |
Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group.
Topics: Aged; Antihypertensive Agents; Atenolol; Chlorthalidone; Diuretics; Double-Blind Method; Electrocard | 1997 |
The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Cohort Studi | 1998 |
[Treatment of chronic heart failure in patients with mitral and aortic valve defects of rheumatic origin].
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agent | 2000 |
Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Disease Progression | 2000 |
Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Atenolol; Atrial Natriuretic Factor; Biomarkers; Double-Blind Method; E | 2001 |
34 other studies available for atenolol and Cardiac Failure
| Article | Year |
|---|---|
Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis.
Topics: Animals; Binding Sites; Cell Line; Cell Membrane Permeability; Cricetinae; Cricetulus; Cytochrome P- | 2006 |
β-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Atenolol; Bisoprolol; Carvedilol; Cause of Dea | 2021 |
β-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies.
Topics: Adrenergic beta-Antagonists; Age Factors; Arrhythmias, Cardiac; Atenolol; Body Mass Index; Californi | 2017 |
[Analysis of the mitochondrial function and ultrastructure in healthy albino mice treated with heart failure medications]
Topics: Animals; Antihypertensive Agents; Atenolol; Cardiotonic Agents; Digoxin; Disease Models, Animal; Diu | 2017 |
[Symptomatic coronary heart disease. Therapy with a beta blocker and ivabradine combination].
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Atenolol; Benzazepines; Coronary Disease; Drug Therapy | 2014 |
Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Disease Models, Animal; Dogs; Drug Therapy, Combinat | 2009 |
Heart rate variability in rats with experimental chronic heart failure and long-term exposure to beta-adrenoblockers.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Benzopyrans; Bisoprolol; Ethanolamines; Heart Failur | 2009 |
Amelioration of cardiac remodeling in congestive heart failure by beta-adrenoceptor blockade is associated with depression in sympathetic activity.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Depression, Chemical; Electrocardiog | 2010 |
β-adrenergic blockade attenuates cardiac dysfunction and myofibrillar remodelling in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blotting, Northern; Ca(2+) Mg(2+)-ATPase; Dose-Respo | 2011 |
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
[Beta blockade plus NO release. Patients with heart failure can be loaded more].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Anti-Arrhythmia Agents; Antihypertensive Agents; Ate | 2002 |
For the patient. New treatments for heart failure in Black people. Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal re
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2003 |
Effect of atenolol therapy on left atrial appendage function in patients with symptomatic mitral stenosis.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Atrial Appendage; Atrial Function, Left; Blood Flow Ve | 2003 |
Restoration of heart rate turbulence by titrated beta-blocker therapy in patients with advanced congestive heart failure: positive correlation with enhanced vagal modulation of heart rate.
Topics: Adrenergic beta-Antagonists; Aged; Analysis of Variance; Atenolol; Case-Control Studies; Chi-Square | 2004 |
Improvement in heart rate turbulence as a measure of response to beta-blocker therapy for heart failure.
Topics: Adrenergic beta-Antagonists; Atenolol; Heart Failure; Heart Rate; Humans; Treatment Outcome | 2004 |
[Influence of therapy with atenolol on lethality of patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Atenolol; Chronic Disease; Echocardiography; Electrocardiography, Ambul | 2005 |
[Cardiac glycosides in complex treatment of patients with heart failure and supraventricular arrhythmias].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Atenolol; Blood Pressure; Ca | 2005 |
[Antihypertensive therapy: risk stratification in diabetes and cardiac diseases].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2006 |
Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin.
Topics: Adrenergic beta-Antagonists; Adverse Drug Reaction Reporting Systems; Aged; Anticoagulants; Atenolol | 2006 |
Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aluminum; Atenolol; California; Carbazo | 2007 |
Changing beta-blockers in heart failure: when is a class not a class?
Topics: Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Carbazoles; Carvedilol; Heart; Heart Failure; Hum | 2008 |
Nifedipine and beta-blockade as a cause of cardiac failure.
Topics: Atenolol; Drug Therapy, Combination; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction | 1982 |
Direct effects of chronic beta-adrenergic receptor blockade on left ventricular and myocyte function in a model of tachycardia-induced congestive heart failure.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Animals; Atenolol; Cardiac Pacing, Artificial; Ca | 1996 |
Long-term beta-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Atenolol; Autonomic Nervous System | 1999 |
Sympathetic activation triggers ventricular arrhythmias in rat heart with chronic infarction and failure.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Analysis of Variance; Animals; Atenolol; | 1999 |
Experience with beta-blocker therapy in patients with advanced heart failure evaluated for HTx.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; | 2000 |
Reversal of deteriorated fractal behavior of heart rate variability by beta-blocker therapy in patients with advanced congestive heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Echocardiography; Electrocardiography, Ambulator | 2001 |
Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Bendroflumethiazide; Cardi | 2001 |
Hemodynamic adjustments in hypertensive patients developing circulatory congestion during beta-adrenergic blockade.
Topics: Adult; Aged; Atenolol; Blood Pressure; Body Weight; Cardiac Output; Drug Evaluation; Female; Heart F | 1979 |
[Neurohumoral changes in patients with heart failure treated chronically with beta-blockers].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Chronic Disease; Digitalis; Diuretics; Drug Eval | 1991 |
[Hemodynamic effects of the nitroprusside test in chronic congestive heart failure treated with long-term beta blocking therapy].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Chronic Disease; Female; Heart Failure; Heart Ra | 1990 |
[Hemodynamic effects of the cold pressor test in patients with heart failure treated with beta blockers for a long time].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Blood Pressure; Cold Temperature; Drug Evaluatio | 1990 |
Atenolol-induced cutaneous vasculitis.
Topics: Atenolol; Drug Eruptions; Female; Heart Failure; Humans; Middle Aged; Vasculitis, Leukocytoclastic, | 1989 |
Improvement of pentobarbital-induced heart failure by MCI-154, a novel and potent cardiotonic agent, in the dog heart-lung preparation.
Topics: Animals; Atenolol; Blood Pressure; Cardiac Output; Cardiotonic Agents; Disease Models, Animal; Dogs; | 1988 |